Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.
Saved in:
| Title: | Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. |
|---|---|
| Authors: | Chatterjee SS; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Linares JF; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Cid-Diaz T; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Duran A; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Khan MIK; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Osrodek M; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Brady NJ; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Reina-Campos M; La Jolla Institute for Immunology (LJI), La Jolla, CA, USA., Marzio A; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Venkadakrishnan VB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Bakht MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Khani F; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Mosquera JM; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA., Robinson BD; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Moyer J; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA., Elemento O; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA., Hsieh AC; Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Genomic Sciences, University of Washington, Seattle, WA, USA.; Department of Medicine, University of Washington, Seattle, WA, USA., Goodrich DW; Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Rickman DS; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Moscat J; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. jom4010@med.cornell.edu.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. jom4010@med.cornell.edu., Diaz-Meco MT; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. mtd4001@med.cornell.edu.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. mtd4001@med.cornell.edu. |
| Source: | Nature communications [Nat Commun] 2024 Nov 20; Vol. 15 (1), pp. 9755. Date of Electronic Publication: 2024 Nov 20. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-53874-2 |
